Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baby-COMET: avalglucosidase alfa in treatment-naive infantile-onset Pompe disease
CTR20220417Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Started Sep 2022; status: active.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on CTR20220417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220417.